Decoding Immunity
Encoding the Future
BayVax Biotech leverages proprietary deep learning frameworks to simulate complex immune interactions, enabling the rapid design and validation of novel antigens for next-generation personalised and broad-spectrum vaccines.
AI-Powered Platform
Our computational platform delivers predictive accuracy that surpasses conventional in-silico models by simulating the fundamental biology of immune recognition.
Immune Discriminator
Simulates peptide-MHC-TCR and peptide-MHC interactions to deliver state-of-the-art prediction.
View WebserverImmune Generator
Enables de novo design of T-cell receptor (TCR) sequences engineered for high-affinity binding.
Immune Toolbox
An integrated suite for the entire computational workflow, from in-silico HLA genotyping to generative design.
Precision Immunotherapy
We are translating computational insights into a new generation of tangible therapeutic strategies for oncology and infectious diseases.
Digital Pipelines
Deploying our validated computational pipelines through strategic licensing and co-development partnerships.
Personalised Vaccines
Developing patient-specific neoantigen vaccines for solid tumors, demonstrating significant PFS extension.
Broad-Spectrum
Designing novel antigens that elicit broad-spectrum, cross-reactive immune responses to diverse pathogens.
Clinical Pipelines
Our research is advancing through preclinical and clinical stages, validating the power of our AI-driven approach.
Pipeline Portfolio
| Candidates | Vaccines | Modality | In-Silico | Preclinical | Clinical |
|---|---|---|---|---|---|
| BXP-001 | Neoantigen Cancer Vaccine | Peptide | IIT | ||
| BVX-COV | Pan-Coronavirus Vaccine | Viral Vector | |||
| BVX-AGE | Senolytic (Anti-Aging) Vaccine | Protein | |||
| BVX-AID | Autoimmune Disease Vaccine | Peptide |
Clinical Milestones
iNATURE Updated Results Released
Updated results of the randomised IIT (iNATURE) have been accepted for presentation at ESMO Congress 2026.
IND Application Initiation
The regulatory pathway is opened for neoantigen vaccines, paving the way for our Investigational New Drug application.
Randomised IIT Launched
The randomised IIT (iNATURE) at HKU-Shenzhen Hospital has started.
Randomised IIT Approved
An investigator-initiated trial Individualized Neoantigen Therapy With Unusual Radiotherapy Enhancement (iNATURE) at The University of Hong Kong-Shenzhen Hospital has been approved by Institutional Review Board.
Single-Arm IIT
Previous Investigator-Initiated Trials in solid tumours (HCC, MSS-CRC) showed significantly extended Progression-Free Survival (PFS).
Scientific Validation
Our work is validated by peer-reviewed research in leading scientific journals.
‡ First author(s) | * Correspondence author(s)
Publications in 20268 papers
Publications in 202510 papers
Publications in 20242 papers
Publications in 20233 papers
Tender Records
Transparent records of our procurement and vendor partnerships.
Results Release: Preclinical Toxicity Study
| Project Title | Preclinical Toxicity Study for Peptide-Based Neoantigen Cancer Vaccine |
| Reference No | TOX-2025-001 |
| Budget | Not exceeding HKD 1,500,000 |
| Deadline | June 6, 2025 |
1. Tender Progress
The tender announcement was officially released on May 14, 2025. By the deadline of June 6, 2025, bid documents from three qualified vendors were received and shortlisted for in-depth evaluation. As of June 13, 2025 the results of this tender has been released.
2. Tender Results
Pharmaron Beijing Co., Ltd. is recommended as the preferred partner for this project.
| Rank | Vendors | Score |
|---|---|---|
| 1 | Pharmaron Beijing Co., Ltd. 康龙化成（北京）新药技术股份有限公司 |
93.67 |
| 2 | Vendor 2 | 87.67 |
| 3 | Vendor 3 | 74.33 |
3. Public Notice & Contact
Public notice period: June 13, 2025 - June 17, 2025.
4. Objections and Complaints
If a bidder or any other interested party has an objection to the bid evaluation results, they must submit a written objection to the tendering entity during the public notice period. The tendering entity will provide a written response within three (3) days of receiving the objection. Bidding activities will be suspended until a response is issued.
If the bidder or interested party remains dissatisfied with the tendering entity’s response, they may file a formal complaint with the relevant industry regulatory authority or public resource trading supervision agency within ten (10) days of receiving the response. The complaint must include the tendering entity’s reply and a written complaint letter.
Closed Tender: Preclinical Toxicity Study (Ref: TOX-2025-001)
| Project Title | Preclinical Toxicity Study for Peptide-Based Neoantigen Cancer Vaccine |
| Reference No | TOX-2025-001 |
| Budget | Not exceeding HKD 1,500,000 |
| Deadline | June 6, 2025 |
1. Background
We seek qualified Contract Research Organizations (CROs) to conduct an IND-enabling toxicity study for a peptide-based neoantigen cancer vaccine. This study is critical to support Investigational New Drug (IND) applications to the Center for Drug Evaluation (CDE) in China and the U.S. Food and Drug Administration (FDA).
2. Scope of Work
- Toxicology Studies: Repeat-Dose Toxicity, Immunogenicity, and Immunotoxicity Assessment.
- Regulatory Compliance: FDA eCTD requirements and CDE guidelines.
3. Eligibility Criteria
- Experience: Proven track record in oncology vaccine preclinical studies
- Regulatory Expertise: Prior successful IND submissions to FDA and CDE
- Facilities: AAALAC-accredited laboratories with GLP certification
4. Evaluation Criteria
| Citerion | Weight |
|---|---|
| Scientific & Technical Merit | 40% |
| Regulatory Compliance | 30% |
| Cost-Effectiveness | 20% |
| Past Performance | 10% |
5. Timeline
- Submission Deadline: June 6, 2025
- Contract Award: June 13, 2025
- Study Start: July 1, 2025
- Final Report Delivery: May 15, 2026
Note: Proposals exceeding the budget cap will be disqualified. Inquiries must be submitted by June 10, 2025.
Our Ecosystem
Uniting with pioneering partners to accelerate breakthrough therapies.
Incubators
Investors
BayVax Proposal 2025
Discover our vision for AI-powered immune programming and the future of personalized medicine.